Philip S Helliwell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4385667/publications.pdf

Version: 2024-02-01

215 papers	12,619 citations	44069 48 h-index	27406 106 g-index
232 all docs	232 docs citations	232 times ranked	6661 citing authors

#	Article	IF	Citations
1	Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis and Rheumatism, 2006, 54, 2665-2673.	6.7	2,811
2	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1060-1071.	5.6	726
3	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	0.9	484
4	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2014, 73, 6-16.	0.9	397
5	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet, The, 2015, 386, 2489-2498.	13.7	389
6	Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis and Rheumatism, 2008, 59, 686-691.	6.7	339
7	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Annals of the Rheumatic Diseases, 2014, 73, 1012-1019.	0.9	314
8	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Annals of the Rheumatic Diseases, 2013, 72, 986-991.	0.9	240
9	Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFÎ± inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2020, 395, 1115-1125.	13.7	211
10	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naÃ¯ve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Annals of the Rheumatic Diseases, 2020, 79, 123-131.	0.9	206
11	Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care and Research, 2010, 62, 965-969.	3.4	201
12	Psoriatic arthritis: state of the art review. Clinical Medicine, 2017, 17, 65-70.	1.9	198
13	Development of a preliminary composite disease activity index in psoriatic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 272-277.	0.9	184
14	Assessment of patients with psoriatic arthritis: A review of currently available measures. Arthritis and Rheumatism, 2004, 50, 24-35.	6.7	171
15	Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase <scp>III</scp> Trial. Arthritis and Rheumatology, 2019, 71, 1112-1124.	5.6	164
16	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet, The, 2018, 392, 2367-2377.	13.7	159
17	Consensus on a core set of domains for psoriatic arthritis. Journal of Rheumatology, 2007, 34, 1167-70.	2.0	155
18	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nature Communications, 2015, 6, 6046.	12.8	149

#	Article	IF	Citations
19	Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Rheumatology and Therapy, 2016, 3, 91-102.	2.3	146
20	A randomized controlled trial of foot orthoses in rheumatoid arthritis. Journal of Rheumatology, 2002, 29, 1377-83.	2.0	134
21	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. Seminars in Arthritis and Rheumatism, 2016, 46, 291-304.	3.4	119
22	Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases. Dermatology and Therapy, 2013, 3, 1-15.	3.0	106
23	The impact of rheumatoid arthritis on foot function in the early stages of disease: a clinical case series. BMC Musculoskeletal Disorders, 2006, 7, 102.	1.9	104
24	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis and Rheumatism, 2009, 61, 1235-1242.	6.7	104
25	Development of a foot impact scale for rheumatoid arthritis. Arthritis and Rheumatism, 2005, 53, 418-422.	6.7	103
26	Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study. Journal of Rheumatology, 2011, 38, 898-903.	2.0	101
27	Development of an assessment tool for dactylitis in patients with psoriatic arthritis. Journal of Rheumatology, 2005, 32, 1745-50.	2.0	100
28	A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2004, 34, 575-584.	3.4	90
29	The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskeletal Disorders, 2013, 14, 101.	1.9	89
30	Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study. Journal of Rheumatology, 2016, 43, 356-361.	2.0	89
31	Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments. Journal of Rheumatology, 2016, 43, 371-375.	2.0	87
32	Sensitivity and specificity of the Classification of Psoriatic Arthritis criteria in early psoriatic arthritis. Arthritis and Rheumatism, 2012, 64, 3150-3155.	6.7	84
33	Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Review of Clinical Immunology, 2018, 14, 719-730.	3.0	83
34	Is There Subclinical Synovitis in Early Psoriatic Arthritis? A Clinical Comparison With Grayâ€Scale and Power Doppler Ultrasound. Arthritis Care and Research, 2014, 66, 432-439.	3.4	79
35	Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Annals of the Rheumatic Diseases, 2021, 80, 185-193.	0.9	79
36	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. Journal of Rheumatology, 2007, 34, 1740-5.	2.0	74

#	Article	IF	Citations
37	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. Arthritis Care and Research, 2014, 66, 1759-1766.	3.4	73
38	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensusâ€Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. Arthritis and Rheumatology, 2018, 70, 345-355.	5.6	72
39	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placeboâ€Controlled Study. Arthritis Care and Research, 2016, 68, 267-274.	3.4	69
40	Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. Rheumatology, 2015, 54, 157-162.	1.9	66
41	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Annals of the Rheumatic Diseases, 2015, 74, 1882-1885.	0.9	64
42	Brief Report: Reduced Joint Counts Misclassify Patients With Oligoarticular Psoriatic Arthritis and Miss Significant Numbers of Patients With Active Disease. Arthritis and Rheumatism, 2013, 65, 1504-1509.	6.7	60
43	Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Annals of the Rheumatic Diseases, 2012, 71, 358-362.	0.9	57
44	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. Journal of Rheumatology, 2007, 34, 1733-9.	2.0	57
45	Comparison of Composite Measures of Disease Activity in Psoriatic Arthritis Using Data From an Interventional Study With Golimumab. Arthritis Care and Research, 2014, 66, 749-756.	3.4	56
46	Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. Journal of the American Academy of Dermatology, 2014, 71, 649-655.	1.2	55
47	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatology, The, 2021, 3, e715-e723.	3.9	53
48	Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. Journal of Rheumatology, 2014, 41, 2277-2285.	2.0	51
49	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. Seminars in Arthritis and Rheumatism, 2018, 47, 654-665.	3.4	50
50	Measuring dactylitis in clinical trials: which is the best instrument to use?. Journal of Rheumatology, 2007, 34, 1302-6.	2.0	50
51	Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions. Journal of Rheumatology, 2008, 35, 472-6.	2.0	49
52	Psoriatic Arthritis Spondylitis Radiology Index: A Modified Index for Radiologic Assessment of Axial Involvement in Psoriatic Arthritis. Journal of Rheumatology, 2009, 36, 1006-1011.	2.0	47
53	Fatigue in psoriatic arthritisÂâ€“Âa cross-sectional study of 246Âpatients from 13Âcountries. Joint Bone Spine, 2016, 83, 439-443.	1.6	47
54	Comprehensive Treatment of Dactylitis in Psoriatic Arthritis. Journal of Rheumatology, 2014, 41, 2295-2300.	2.0	45

#	Article	IF	Citations
55	Pathophysiology, assessment and treatment of psoriatic dactylitis. Nature Reviews Rheumatology, 2019, 15, 113-122.	8.0	45
56	Assessing Disease Activity in Psoriatic Arthritis: A Literature Review. Rheumatology and Therapy, 2019, 6, 23-32.	2.3	43
57	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLAâ€“B27 Status?. Arthritis Care and Research, 2021, 73, 856-860.	3.4	43
58	Foot orthoses in the treatment of symptomatic midfoot osteoarthritis using clinical and biomechanical outcomes: a randomised feasibility study. Clinical Rheumatology, 2016, 35, 987-996.	2.2	41
59	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naÃ¯ve or TNFÎ± inhibitor-experienced. RMD Open, 2021, 7, e001457.	3.8	41
60	Classification of the spondyloarthropathies. Current Opinion in Rheumatology, 2005, 17, 395-399.	4.3	38
61	Treating to target in psoriatic arthritis: how to implement in clinical practice. Annals of the Rheumatic Diseases, 2016, 75, 640-643.	0.9	38
62	Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naÃ¯ve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. RMD Open, 2020, 6, e001149.	3.8	38
63	Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis. Rheumatology and Therapy, 2015, 2, 1-16.	2.3	37
64	Outcome measures in psoriatic arthritis. Journal of Rheumatology, 2005, 32, 2262-9.	2.0	37
65	Problems with the definition of axial and peripheral disease patterns in psoriatic arthritis. Journal of Rheumatology, 2005, 32, 974-7.	2.0	36
66	Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) â€" Report of the OMERACT 10 PsA Special Interest Group. Journal of Rheumatology, 2011, 38, 1496-1501.	2.0	35
67	Patient global assessment in psoriatic arthritis â€“ what does it mean? An analysis of 223Âpatients from the Psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine, 2016, 83, 335-340.	1.6	35
68	Development of Screening Tools to Identify Psoriatic Arthritis. Current Rheumatology Reports, 2010, 12, 295-299.	4.7	34
69	Development of a Disease Activity and Responder Index for Psoriatic Arthritis â€" Report of the Psoriatic Arthritis Module at OMERACT 11. Journal of Rheumatology, 2014, 41, 782-791.	2.0	34
70	Patient Involvement in Outcome Measures for Psoriatic Arthritis. Current Rheumatology Reports, 2014, 16, 418.	4.7	34
71	Enhanced Patient Involvement and the Need to Revise the Core Set â€" Report from the Psoriatic Arthritis Working Group at OMERACT 2014. Journal of Rheumatology, 2015, 42, 2198-2203.	2.0	34
72	Therapies for dactylitis in psoriatic arthritis. A systematic review. Journal of Rheumatology, 2006, 33, 1439-41.	2.0	34

#	Article	IF	Citations
73	Debridement of painful forefoot plantar callosities in rheumatoid arthritis: the CARROT randomised controlled trial. Clinical Rheumatology, 2013, 32, 567-574.	2.2	33
74	Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review. Journal of Rheumatology, 2008, 35, 1438-42.	2.0	33
75	Itâ€™s not just the joints, itâ€™s the whole thing: qualitative analysis of patientsâ€™ experience of flare in psoriatic arthritis. Rheumatology, 2015, 54, 1448-1453.	1.9	32
76	Disease measurement â€“ enthesitis, skin, nails, spine and dactylitis. Best Practice and Research in Clinical Rheumatology, 2010, 24, 659-670.	3.3	31
77	Ixekizumab treatment of biologic-naÃ¯ve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology, 2020, 59, 2774-2784.	1.9	31
78	Psoriasis Epidemiology Screening Tool (PEST): A Report from the GRAPPA 2009 Annual Meeting. Journal of Rheumatology, 2011, 38, 551-552.	2.0	30
79	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110579.	2.7	30
80	Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tightâ€Control Clinical Trial and an Observational Cohort. Arthritis Care and Research, 2018, 70, 1198-1205.	3.4	29
81	Dactylitis: Pathogenesis and clinical considerations. Current Rheumatology Reports, 2006, 8, 338-341.	4.7	27
82	Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open, 2022, 8, e002074.	3.8	27
83	Current concepts and unmet needs in psoriatic arthritis. Clinical Rheumatology, 2018, 37, 297-305.	2.2	26
84	Assessment of disease activity in psoriatic arthritis. Clinical and Experimental Rheumatology, 2015, 33, S44-7.	0.8	26
85	Comparison of screening questionnaires to identify psoriatic arthritis in a primary-care population: a cross-sectional study. British Journal of Dermatology, 2016, 175, 542-548.	1.5	25
86	Development of Criteria to Distinguish Inflammatory from Noninflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2013 Annual Meeting. Journal of Rheumatology, 2014, 41, 1249-1251.	2.0	24
87	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. Journal of Rheumatology, 2016, 43, 965-969.	2.0	24
88	Modification of the Psoriatic Arthritis Disease Activity Score (PASDAS). Annals of the Rheumatic Diseases, 2018, 77, 467-468.	0.9	24
89	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Research and Therapy, 2018, 20, 242.	3.5	24
90	Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patientsâ€™ health-related quality of life and productivity. BMC Rheumatology, 2018, 2, 24.	1.6	24

#	Article	IF	Citations
91	What Should Be the Primary Target of â€œTreat to Targetâ€•in Psoriatic Arthritis?. Journal of Rheumatology, 2019, 46, 38-42.	2.0	24
92	Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. RMD Open, 2021, 7, e001486.	3.8	24
93	Axial disease in psoriatic arthritis. Rheumatology, 2020, 59, 1193-1195.	1.9	23
94	Relationship of psoriatic arthritis with the other spondyloarthropathies. Current Opinion in Rheumatology, 2004, 16, 344-349.	4.3	22
95	Use of conservative and surgical foot care in an inception cohort of patients with rheumatoid arthritis. Rheumatology, 2011, 50, 1586-1595.	1.9	22
96	Composite Measures in Psoriatic Arthritis: A Report from the GRAPPA 2009 Annual Meeting. Journal of Rheumatology, 2011, 38, 540-545.	2.0	22
97	Clinical Examination, Ultrasound and MRI Imaging of The Painful Elbow in Psoriatic Arthritis and Rheumatoid Arthritis: Which is Better, Ultrasound or MR, for Imaging Enthesitis?. Rheumatology and Therapy, 2017, 4, 71-84.	2.3	22
98	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. Arthritis Care and Research, 2014, 66, 1410-1416.	3.4	21
99	The Diagnosis and Treatment of Adult Patients with SAPHO Syndrome: Controversies Revealed in a Multidisciplinary International Survey of Physicians. Rheumatology and Therapy, 2020, 7, 883-891.	2.3	21
100	Development of diagnostic criteria for psoriatic arthritis: Methods and process. Current Rheumatology Reports, 2004, 6, 299-305.	4.7	20
101	The predictors of foot ulceration in patients with rheumatoid arthritis: a preliminary investigation. Clinical Rheumatology, 2008, 27, 1423-1428.	2.2	20
102	A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis		

#	Article	IF	Citations
109	Methodological considerations for a randomised controlled trial of podiatry care in rheumatoid arthritis: lessons from an exploratory trial. BMC Musculoskeletal Disorders, 2007, 8, 109.	1.9	18
110	Established Psoriatic Arthritis: Clinical Aspects. Journal of rheumatology Supplement, The, 2009, 83, 21-23.	2.2	18
111	A case series to describe the clinical characteristics of foot ulceration in patients with rheumatoid arthritis. Clinical Rheumatology, 2012, 31, 541-545.	2.2	18
112	Benchmarking Care in Psoriatic Arthritis â€" The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. Journal of Rheumatology, 2017, 44, 674-678.	2.0	18
113	Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients. Rheumatology and Therapy, 2019, 6, 521-528.	2.3	18
114	The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. Annals of the Rheumatic Diseases, 2017, 76, 1688-1692.	0.9	17
115	The Composite DAS Score is Impractical to use in Daily Practice. Journal of Clinical Rheumatology, 2009, 15, 223-225.	0.9	16
116	The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome. Rheumatology, 2016, 55, 2277-2278.	1.9	16
117	The predictors of foot ulceration in patients with rheumatoid arthritis. Clinical Rheumatology, 2014, 33, 615-621.	2.2	15
118	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open-label, randomised controlled trial. Lancet, The, 2014, 383, S36.	13.7	15
119	Treat to Target in Psoriatic Arthritisâ€"Evidence, Target, Research Agenda. Current Rheumatology Reports, 2015, 17, 517.	4.7	15
120	Psoriasis flare with corticosteroid use in psoriatic arthritis. British Journal of Dermatology, 2016, 174, 219-221.	1.5	15
121	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. Arthritis and Rheumatology, 2022, 74, 1535-1543.	5.6	15
122	Magnetic Resonance Arthrography of Lesser Metatarsophalangeal Joints in Patients with Rheumatoid Arthritis: Relationship to Clinical, Biomechanical, and Radiographic Variables. Journal of Rheumatology, 2012, 39, 1786-1791.	2.0	14
123	Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis. Arthritis Care and Research, 2017, 69, 1700-1705.	3.4	14
124	Focussing on the foot in psoriatic arthritis: pathology and management options. Expert Review of Clinical Immunology, 2018, 14, 21-28.	3.0	14
125	Remission in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2012, 89, 19-21.	2.2	13
126	Development of a Flare Instrument for Use in Psoriatic Disease: A Report from the 2015 GRAPPA Annual Meeting. Journal of Rheumatology, 2016, 43, 974-978.	2.0	13

#	Article	IF	Citations
127	Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity. Arthritis Care and Research, 2018, 70, 797-800.	3.4	13
128	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Rheumatology, 2021, 60, 1137-1147.	1.9	13
129	Developing classification criteria for peripheral joint psoriatic arthritis. Step I. Establishing whether the rheumatologist's opinion on the diagnosis can be used as the "gold standard". Journal of Rheumatology, 2006, 33, 552-7.	2.0	13
130	Classification and categorisation of psoriatic arthritis. Clinical Rheumatology, 2008, 27, 1211-1216.	2.2	12
131	Costâ€Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial. Arthritis Care and Research, 2018, 70, 462-468.	3.4	12
132	Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1530-1534.	2.4	11
133	Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. Arthritis Care and Research, 2020, 72, 1579-1588.	3.4	11
134	The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains?. Annals of the Rheumatic Diseases, 2015, 74, e66-e66.	0.9	10
135	Physicianâ€™s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. Journal of Rheumatology, 2018, 45, 1256-1262.	2.0	10
136	Assessment of Enthesitis in Psoriatic Arthritis. Journal of Rheumatology, 2019, 46, 869-870.	2.0	10
137	Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial. Journal of Rheumatology, 2020, 47, 1338-1343.	2.0	10
138	Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis. Annals of the Rheumatic Diseases, 2022, 81, 490-495.	0.9	10
139	A discrete choice experiment to explore patientsâ€™ willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. Clinical Rheumatology, 2016, 35, 2967-2974.	2.2	9
140	Replication of a distinct psoriatic arthritis risk variant at theIL23Rlocus. Annals of the Rheumatic Diseases, 2016, 75, 1417-1418.	0.9	9
141	The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes. BMC Musculoskeletal Disorders, 2017, 18, 303.	1.9	9
142	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. Arthritis Research and Therapy, 2021, 23, 94.	3.5	9
143	Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. Journal of Rheumatology, 2021, , jrheum.201674.	2.0	9
144	GRAPPA Responder Index Project (GRACE): A Report from the GRAPPA 2011 Annual Meeting. Journal of Rheumatology, 2012, 39, 2196-2197.	2.0	8

#	Article	IF	Citations
145	Screening psoriatic arthritis tools: analysis of the Early Arthritis for Psoriatic Patients questionnaire. Rheumatology, 2015, 54, 200-202.	1.9	8
146	Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. Rheumatology, 2020, 59, 807-810.	1.9	8
147	Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting. Journal of Rheumatology, 2021, , jrheum.201672.	2.0	8
148	Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial. Lancet Rheumatology, The, 2022, 4, e252-e261.	3.9	8
149	Psoriasis and Psoriatic Arthritis Educational Initiatives: An Update from the 2013 GRAPPA Annual Meeting. Journal of Rheumatology, 2014, 41, 1240-1243.	2.0	7
150	Plantar plate pathology is associated with erosive disease in the painful forefoot of patients with rheumatoid arthritis. BMC Musculoskeletal Disorders, 2017, 18, 308.	1.9	7
151	Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. ACR Open Rheumatology, 2020, 2, 543-554.	2.1	7
152	Patient Reported Outcomes in Chronic Inflammatory Diseases: Current State, Limitations and Perspectives. Frontiers in Immunology, 2021, 12, 614653.	4.8	7
153	GRAPPA 2018 Project Report. Journal of Rheumatology, 2019, 95, 54-57.	2.0	7
154	GRAPPA 2019 Project Report. Journal of Rheumatology, 2020, 96, 53-57.	2.0	7
155	Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). Trials, 2020, 21, 155.	1.6	6
156	A clinical and radiographic comparison of patients with psoriatic arthritis from different ethnic backgrounds. Rheumatology, 2021, 60, 340-345.	1.9	6
157	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology, 2022, 61, e255-e266.	1.9	6
158	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology, 2023, 62, 606-616.	1.9	6
159	GRAPPA 2013 Annual Meeting, Rheumatology Updates: Psoriatic Arthritis (PsA) Biomarker Project, Arthritis Mutilans, PsA-Peripheral Spondyloarthritis Epidemiology Project. Journal of Rheumatology, 2014, 41, 1244-1248.	2.0	5
160	Diurnal variation of gait in patients with rheumatoid arthritis: The DIVIGN study. Clinical Biomechanics, 2014, 29, 811-814.	1.2	5
161	Interleukin-17 inhibition in psoriatic arthritis. Lancet, The, 2015, 386, 1114-1116.	13.7	5
162	Interpreting outcome following foot surgery in people with rheumatoid arthritis. Journal of Foot and Ankle Research, 2016, 9, 20.	1.9	5

#	Article	IF	Citations
163	To Lump or Split When Assessing Psoriatic Arthritis â€" Not Mutually Exclusive?. Journal of Rheumatology, 2020, 47, 307-309.	2.0	5
164	Best-practice Indicators in Psoriatic Disease Care. Journal of Rheumatology, 2019, 95, 38-45.	2.0	5
165	Comparing the Visual Analog Scale and the Numerical Rating Scale in Patient-reported Outcomes in Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, 836-840.	2.0	5
166	Comment on: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology, 2010, 49, 1793-1794.	1.9	4
167	Joint Orthopaedic and Rheumatology Clinics: Evidence to Support the Guidelines. Musculoskeletal Care, 2011, 9, 180-183.	1.4	4
168	Screening for Psoriatic Arthritis in People with Psoriasis. Journal of Rheumatology, 2015, 42, 736-738.	2.0	4
169	Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. Journal of Rheumatology, 2021, 48, 1268-1271.	2.0	4
170	Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Research and Therapy, 2022, 24, 40.	3.5	4
171	Treat-to-target in psoriatic arthritisâ€"cost-effective in the biosimilar era. Lancet Rheumatology, The, 2022, 4, e390-e391.	3.9	4
172	Human nocturnal blood melatonin and liver acetylation status. Journal of Pineal Research, 1991, 10, 14-17.	7.4	3
173	GRAPPA 2015 Research and Education Project Reports. Journal of Rheumatology, 2016, 43, 979-985.	2.0	3
174	Verna Wright: father of the spondyloarthropathies. Annals of the Rheumatic Diseases, 2019, 78, 454-455.	0.9	3
175	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naÃ¯ve) psoriatic disease: a GRAPPA initiative. Rheumatology Advances in Practice, 2020, 4, rkaa032.	0.7	3
176	Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study. Journal of Rheumatology, 2021, , jrheum.201675.	2.0	3
177	Pustular Psoriasis and Associated Musculoskeletal Disorders. Journal of Rheumatology, 2021, , jrheum.201673.	2.0	3
178	Correspondence on â€˜No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related â€˜physician-reported spondylitisâ€™?â€™. Annals of the Rheumatic Diseases, 2023, 82, e187-e187.	0.9	3
179	Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study. Patient, 0, , .	2.7	3
180	Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: Comment on the article by Clegg et al. Arthritis and Rheumatism, 1997, 40, 1911-1912.	6.7	2

#	Article	IF	Citations
181	Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2014 Annual Meeting. Journal of Rheumatology, 2015, 42, 1041-1043.	2.0	2
182	Presidential Round Table: A Report from the GRAPPA Annual Meeting. Journal of Rheumatology, 2016, 43, 986-989.	2.0	2
183	GRAPPA 2016 Project Report. Journal of Rheumatology, 2017, 44, 706-710.	2.0	2
184	Werner syndrome: a rare cause of osteoporosis in a young female. Rheumatology, 2018, 57, 2021-2021.	1.9	2
185	The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register. BMC Rheumatology, 2021, 5, 19.	1.6	2
186	Aiming for remission in psoriatic arthritis. International Journal of Clinical Rheumatology, 2014, 9, 147-153.	0.3	1
187	The NICE appraisal of ustekinumab for treating psoriatic arthritis. British Journal of Health Care Management, 2016, 22, 68-71.	0.2	1
188	An educational leaflet improves response to invitation for screening for arthritis in patients with psoriasis in primary care, but only in practices in the most deprived areas. Clinical Rheumatology, 2017, 36, 719-723.	2.2	1
189	AB0742â€…ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS. , 2019, , .		1
190	P262â€ƒGuselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naÃ¯ve or prior TNFÎ± inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study. Rheumatology, 2020, 59, .	1.9	1
191	P174â€ƒUpadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. Rheumatology, 2021, 60, .	1.9	1
192	Measuring Physical Function in Psoriatic Arthritis: Comparing the Multidimensional Health Assessment Questionnaire to the Health Assessment Questionnaireâ€“Disability Index. Journal of Rheumatology, 2021, 48, jrheum.200927.	2.0	1
193	Molecular and cellular regulation of psoriatic inflammation. Clinical Science, 2022, 136, 935-952.	4.3	1
194	Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. Rheumatology, 0, , .	1.9	1
195	Biomechanics of the foot in rheumatoid arthritis: Identifying abnormal function and the factors that predict disease impact. Clinical Biomechanics, 2008, 23, 719-720.	1.2	0
196	The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite Disease Index Project (GRACE). Psoriasis Forum, 2011, 17a, 216-219.	0.1	0
197	I58.â€ƒTherapy of PSA: What is New and How Can We Treat to Target?. Rheumatology, 2014, 53, i13-i13.	1.9	0
198	177.â€ƒMechanical Factors that May Contribute to Toe Dactylitis in Patients with Psoriatic Athritis. Rheumatology, 2014, 53, i125-i126.	1.9	0

#	Article	IF	Citations
199	179.â€ƒFoot Orthoses in the Treatment of Symptomatic Midfoot Osteoarthritis Using Clinical and Biomechanical Outcomes: A Feasibility Study. Rheumatology, 2014, 53, i126-i126.	1.9	0
200	I58â€ƒPsoriatic Arthritis: Anti-Tumour Necrosis Factor and Beyond. Rheumatology, 0, , .	1.9	0
201	I111â€ƒStrategies for the Use of Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis, Including Treat to Target. Rheumatology, 0, , .	1.9	0
202	More than meets the eye?. Lancet, The, 2016, 388, e15.	13.7	0
203	L.C. Coates and P.S. Helliwell reply. Journal of Rheumatology, 2016, 43, 1766.2-1766.	2.0	0
204	Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?. Clinical Rheumatology, 2017, 36, 1803-1810.	2.2	0
205	069.â€ƒCONSTRUCT VALIDITY, RESPONSIVENESS AND MINIMALLY IMPORTANT DIFFERENCE OF THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 IN PSORIATIC ARTHRITIS. Rheumatology, 2017, 56, .	1.9	0
206	A new era for collaboration?. Rheumatology, 2018, 57, 775-776.	1.9	0
207	AB0745â€…ASSESSMENT OF DISEASE ACTIVITY USING RAPID3 AND EVALUATION OF TREATMENT EFFECT OF GUSELKUMAB IN PATIENTS WITH PSA: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL. , 2019, , .		0
208	SAT0387â€…CONSISTENT EFFICACY IN PATIENT SUBGROUPS ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS: RESULTS FROM A PHASE 2 STUDY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. , 2019, , .		0
209	BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. Rheumatology Advances in Practice, 2020, 4, rkaa043.	0.7	0
210	P277â€ƒAssessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial. Rheumatology, 2020, 59, .	1.9	0
211	GRAPPA 2020 Update From the Education Committee. Journal of Rheumatology, 2021, , jrheum.201678.	2.0	0
212	P172â€ƒQuality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment. Rheumatology, 2021, 60, .	1.9	0
213	Development of an Instrument for Patient Self-assessment in Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, jrheum.210010.	2.0	0
214	Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores. Clinical Trials, 2021, 18, 541-551.	1.6	0
215	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. Journal of Rheumatology, 2022, , .	2.0	0